Washington University School of Medicine

Digital Commons@Becker
2020-Current year OA Pubs

Open Access Publications

6-1-2021

Multiparametric early detection and prediction of cardiotoxicity
using myocardial strain, T1 and T2 mapping, and biochemical
markers: A longitudinal cardiac resonance imaging study during 2
years of follow-up
Sorin Giusca
GRN Academic Teaching Hospital Weinheim

Grigorios Korosoglou
GRN Academic Teaching Hospital Weinheim

Moritz Montenbruck
Marien Hospital

Blaž Geršak
University of Ljubljana

Arne Kristian Schwarz
Marien Hospital
Follow this and additional works at: https://digitalcommons.wustl.edu/oa_4
Part of the Medicine and Health Sciences Commons
See next page for additional authors

Recommended Citation
Giusca, Sorin; Korosoglou, Grigorios; Montenbruck, Moritz; Geršak, Blaž; Schwarz, Arne Kristian; Esch,
Sebastian; Kelle, Sebastian; Wülfing, Pia; Dent, Susan; Lenihan, Daniel; and Steen, Henning,
"Multiparametric early detection and prediction of cardiotoxicity using myocardial strain, T1 and T2
mapping, and biochemical markers: A longitudinal cardiac resonance imaging study during 2 years of
follow-up." Circulation: Cardiovascular Imaging. 14, 6. e012459 (2021).
https://digitalcommons.wustl.edu/oa_4/285

This Open Access Publication is brought to you for free and open access by the Open Access Publications at
Digital Commons@Becker. It has been accepted for inclusion in 2020-Current year OA Pubs by an authorized
administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.

Authors
Sorin Giusca, Grigorios Korosoglou, Moritz Montenbruck, Blaž Geršak, Arne Kristian Schwarz, Sebastian
Esch, Sebastian Kelle, Pia Wülfing, Susan Dent, Daniel Lenihan, and Henning Steen

This open access publication is available at Digital Commons@Becker: https://digitalcommons.wustl.edu/oa_4/285

Circulation: Cardiovascular Imaging

ORIGINAL ARTICLE

Multiparametric Early Detection and Prediction of
Cardiotoxicity Using Myocardial Strain, T1 and T2
Mapping, and Biochemical Markers
A Longitudinal Cardiac Resonance Imaging Study During 2 Years of Follow-Up
BACKGROUND: Our goal was to evaluate the ability of cardiovascular
magnetic resonance for detecting and predicting cardiac dysfunction in
patients receiving cancer therapy. Left ventricular ejection fraction, global
and regional strain utilizing fast-strain-encoded, T1 and T2 mapping, and
cardiac biomarkers (troponin and BNP [brain natriuretic peptide]) were
analyzed.
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METHODS: Sixty-one patients (47 with breast cancer, 11 with nonHodgkin lymphoma, and 3 with Hodgkin lymphoma) underwent
cardiovascular magnetic resonance scans at baseline and at regular
intervals during 2 years of follow-up. The percentage of all left ventricular
myocardial segments with strain ≤−17% (normal myocardium [%])
was analyzed. Clinical cardiotoxicity (CTX) and sub-CTX were defined
according to standard measures.
RESULTS: Nine (15%) patients developed CTX, 26 (43%) had sub-CTX.
Of the 35 patients with CTX or sub-CTX, 24 (69%) were treated with
cardioprotective medications and showed recovery of cardiac function.
The amount of normal myocardium (%) exhibited markedly higher
accuracy for the detection of CTX and sub-CTX compared with left
ventricular ejection fraction, T1, and T2 mapping as well as troponin I
(∆areas under the curve=0.20, 0.24, and 0.46 for normal myocardium
(%) versus left ventricular ejection fraction, troponin I, and T1 mapping,
P<0.001 for all). In addition, normal myocardium (%) at baseline
accurately identified patients with subsequent CTX (P<0.001), which was
not achieved by any other markers.
CONCLUSIONS: Normal myocardium (%) derived by fast-strain-encoded
cardiovascular magnetic resonance, is an accurate and sensitive tool that
can establish cardiac safety in patients with cancer undergoing cardiotoxic
chemotherapy not only for the early detection but also for the prediction
of those at risk of developing CTX.
REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier:
NCT03543228.
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CLINICAL PERSPECTIVE
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Advances in oncology have significantly improved
the mortality rates of patients with cancer.
However, these positive trends are offset by the
possible cardiotoxic effects of chemotherapy.
These adverse effects of chemotherapy on the
cardiovascular system are summarized under the
term cardiotoxicity and can be a common cause
of death after successful treatment for cancer.
The early detection and especially the prediction
of cardiotoxicity, therefore, represent an unmet
clinical need. In our study, we showed that cardiovascular magnetic resonance is an excellent
tool for serial monitoring the cardiovascular
health of patients with cancer. In this regard, we
found that the amount of normal myocardium
(%) measured using fast-strain-encoded and
defined as percentage of segments with normal
strain (≤−17%) can accurately identify patients
who develop clinical and subclinical cardiotoxicity and is also the only independent predictor of cardiotoxicity. In addition, we found that
this imaging marker, if measured just before the
start of cardiovascular protective therapies (ie,
ACE [angiotensin-converting enzyme]-inhibitors/
angiotensin II receptor blockers or β-blocker) can
accurately predict recovery from cardiotoxicity. In
conclusion, normal myocardium (%) can fulfill a
triple diagnostic function in such patients, aiding
(1) early cardiotoxicity detection, (2) cardiotoxicity
prediction before chemotherapy initiation using
baseline normal myocardium (%) values, and (3)
prediction of recovery from cardiotoxicity after
established cardiotoxicity using normal myocardium (%) before the initiation of cardioprotective
treatment. Because all cardiovascular magnetic
resonance measures can be performed without
the use of ionizing radiation and even using a
purely noncontrast cardiovascular magnetic resonance protocol, the potential of our findings for
translation into the clinical realm is high.

A

s a result of major advancements in cancer
therapeutics over the past 2 decades, there
has been substantial improvement in cancer-related mortality; however, there are important
long-term sequelae from these treatments including cardiovascular dysfunction.1 Interestingly, cardiac
damage because of cancer therapy can be a common
cause of death, especially after ≥5 years of successful treatment for cancer.2 Thus, the early recognition
or even the prediction of myocardial damage due to
cardiotoxicity may allow the proactive modification of

treatment regimens or accurate identification of those
who would benefit from preventive cardioprotection.
Indeed, this has become a top 10 priority within the
discipline of Cardio-Oncology.3
Several imaging parameters and biomarkers were
shown to be useful for the diagnostic workup and
monitoring of cardiotoxicity.4 Measurement of left ventricular ejection fraction (LVEF) is the most commonly
used parameter in clinical practice.5 Although LVEF is a
widely accepted marker of global systolic performance,
relevant reductions in LVEF are seen only when irreversible damage to the myocardium has occurred.6,7 Myocardial strain, however, can detect subclinical damage
due to cancer therapy before LVEF changes occur.8 In
this regard, the versatility of cardiovascular magnetic
resonance imaging (CMR) provides the acquisition of
LVEF, strain, and tissue characteristics, including T1 and
T2 mapping in a single examination and without exposing the patients to contrast agents or radiation. This
makes CMR an ideal tool for longitudinal studies in
such patients.9 Several studies have demonstrated the
ability of CMR to detect subclinical cardiotoxicity (subCTX).10 However, limited data are available comparing
the ability of strain and T1 or T2 mapping, whereas the
ability of such markers for the prediction of cardiotoxicity or recovery from cardiotoxicity (REC) of cardiac function during treatment with cardioprotective agents is
largely unknown.
Therefore, the aim of this study was to prospectively
evaluate and compare the ability of LVEF, myocardial
strain using fast-strain-encoded (SENC), T1 and T2
mapping parameters, and cardiac biomarkers for the
early detection and monitoring of cardiac dysfunction
in patients who undergo chemotherapy due to breast
cancer and lymphoma. Additionally, we sought to explore if baseline LV myocardial strain by CMR can accurately identify those patients at high risk for cardiotoxicity during chemotherapy for cancer.

METHODS
The data that support the findings of this study are
available from the corresponding authors upon reasonable request.
The PREFECT Study (Proactive Evaluation of Function
to Evade Cardiotoxicity) was a prospective, single-center, nonrandomized study that included patients with
cancer scheduled to receive chemotherapy. Patients
must have had a CMR examination (including fastSENC–derived myocardial strain and T1 and T2 mapping acquisitions) before starting chemotherapy and at
regular intervals of 3 to 6 months thereafter. The study
was approved by the local ethics committee (PV5292)
of the University Hospital Hamburg, all patients gave
written informed consent, and the study complied with
the Declaration of Helsinki.
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Study Population
Patients with breast cancer, Non-Hodgkin, or Hodgkin
lymphoma receiving chemotherapy, all being treated with
curative intent, were included in this study. Exclusion criteria included age<18 or >80 years, inability to give informed
consent, pregnancy, previous chemotherapy, contraindications to CMR examination, and renal failure with a glomerular filtration rate<30 mL/(kg·m2).
Before initiating chemotherapy, clinical, and demographic
data, including cardiovascular risk factors, such as arterial hypertension, dyslipidemia, diabetes, family history of
coronary artery disease, and smoking status were collected.
Medications were recorded with a focus on cardioprotective
medication, including ACE (angiotensin-converting enzyme)inhibitors or angiotensin II receptor blockers (ARBs) and βblockers. Blood samples were drawn and a complete blood
count, creatinine, BNP (brain natriuretic peptide), and troponin I were measured at baseline. Before starting chemotherapy, a complete CMR examination was performed in all
patients.

Chemotherapy

Downloaded from http://ahajournals.org by on September 15, 2022

Anticancer treatments were managed at the discretion of the
attending oncologist. Patients with breast cancer were treated
with a total of 4 cycles of epirubicin and cyclophosphamide
every 3 weeks followed by 12 weekly cycles of paclitaxel (epirubicin, cyclophosphamide, paclitaxel), with a few receiving
dose-dense (every 2 weeks) epirubicin, cyclophosphamide,
paclitaxel (total 8 cycles). Patients with HER2+ breast cancer were treated with trastuzumab. Radiation therapy was
additionally performed based on current guidelines and at
the discretion of the attending oncology team. Non-Hodgkin
lymphoma patients were treated with cyclophosphamide,
doxorubicin, vincristine, and prednisone with the monoclonal antibody rituximab (rituximab - cyclophosphamide, doxorubicine, vincristien and prednison), whereas patients with
Hodgkin lymphoma were treated with anthracycline-based
therapy with or without radiation therapy.

CMR Examination
All CMR examinations were performed using a 1.5 Tesla
Achieva MRI scanner (Philips Healthcare, Best, the Netherlands).
A detailed CMR protocol for conventional, fast-SENC, and
mapping is presented in Appendix A. Time spent was ≈10 to
12 minutes for both baseline and follow-up CMR scans. T1
maps were acquired using a standard Modified Look-Locker
Inversion Recovery 5s(3s)3s T1-native sequence in standard
midventricular short-axis views. T2 Maps were acquired using
an mGRASE sequence with 9 echos. Lastly, 6 fast-SENC acquisitions were performed (3 short axes—basal, mid, and apical
and 3 long axes—4 chambers, 2 chambers, and 3 chambers).

Analysis of CMR Data
CMR data were imported in a dedicated software (CVI
42, Circle Cardiovascular Imaging, Inc, Calgary, Canada).
Conventional and morphological parameters were extracted
from cine images as can be found in the appendix. T1
and T2 values were extracted from the septal segments of

midventricular short-axis T1 and T2 mapping acquisitions.
Fast-SENC images were assessed using dedicated software
(Myocardial Solutions, Inc, Morrisville, NC). The analysis of the
data for extracting longitudinal and circumferential strain can
also be found in the appendix. Longitudinal strain (LS) was
derived from the short-axis acquisitions and circumferential
strain (CS) from long-axis acquisitions. Global LS (GLS) was
calculated as an average of the 16 segments with longitudinal
strain and global CS as an average of the 21 segments measuring circumferential strain, as described previously.11
As reported in previous studies, a value for LS or CS in any
segment ≤−17% was considered normal.12,13 The percentage
of normal myocardium in each patient is the ratio between
the total number of segments expressing normal myocardium, that is, LS≤−17% (out of n=16) and CS≤−17% (out of
n=21) divided by the total number of segments analyzed (37
segments in total), as described previously11:
Normal myocardium =
Segments with circumferential and longitudinal strain ≤ − 17%
37

Strain values in longitudinal and circumferential directions
are negative and are reported as such in our results section. Throughout the text, however, we refer to the absolute
strain values (ie, higher strain values standing for increased
deformation).

CMR and Clinical Follow-Up Examinations
Patients were followed at regular time intervals clinically and
with CMR. For the CMR examination, patients were planned
at regular intervals of 3 to 6 months, or when a cumulative
dose of anthracycline greater than 150 mg/m2 was reached,
or when clinically indicated.14 Clinical follow-up included
medical history with New York Heart Association class assessment and standard clinical examination as well as blood testing to assess cardiac biomarkers (troponin I and BNP). With
follow-up CMR studies, morphology and function, including
strain by fast-SENC and T1 and T2 mapping were assessed.

Definitions and Clinical End Points for
Cardiotoxicity and Sub-CTX
Cardiotoxicity was diagnosed based on current imaging recommendations for significant cardiac damage resulting from
chemotherapy.5,15 Thus, cardiotoxicity was defined as a reduction of at least 10 percentage points of LVEF to below 53%
in patients who develop symptoms of heart failure such as
fatigue, dyspnea, or edema. Sub-CTX was defined as a reduction in the average GLS value of at least 15% compared with
baseline GLS in patients who are asymptomatic. The group
without cardiotoxicity (no cardiotoxicity) had neither a change
in LVEF or GLS at these thresholds.

Initiation of Cardioprotective Therapies
and Prediction of REC
Patients who developed Sub-CTX or cardiotoxicity (at clinical or
CMR examination) were started on cardioprotective medications
(ACE inhibitors or ARBs or β-blocker) at the discretion of the
attending cardiologist. If improvement of myocardial function
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was reached, patients were classified as achieving REC. The ability of CMR variables, which were acquired before treatment initiation with cardioprotective therapies, such as β-blockers, ACE
inhibitors, or the combination of both, was tested for the prediction for REC versus non-REC in patients with cardiotoxicity.

Statistical Analysis

Downloaded from http://ahajournals.org by on September 15, 2022

Data are presented as mean±SD for normally distributed continuous variables, otherwise as median and interquartile range,
or as counts and percentage for categorical variables. The
Kolmogorov-Smirnov test was used to test for normal distribution. Differences between ≥3 groups of continuous variables
were tested using ANOVA with the Scheffé test for post hoc
analysis. The Mann-Whitney test was used to compare ordinal
variables and Fisher test to compare nominal variables. KruskalWallis tests were used to compare differences between patients
with cardiotoxicity versus those without cardiotoxicity and REC.
In addition, Conover post hoc analysis was used to compare
the 3 different groups with each other. Receiver operating
characteristic (ROC) analysis was performed to determine the
optimal cutoff points for sensitivity and specificity in predicting the development of cardiotoxicity. Comparison of the areas
under the curve of paired data ROC curves was performed
using the DeLong method.16 Multiple regression analysis with
an enter method was performed to test the ability of clinical
and CMR variables and clinical status to predict patients who
develop cardiotoxicity (both clinical and subclinical). In addition,
the same type of analysis was employed to test the variables
associated with REC in patients who experienced cardiotoxicity after initiation of chemotherapy. In addition, Cox proportional hazard regression models were constructed for clinical
variables, CMR parameters, and biomarkers. Kaplan-Meyer
analyses were used to predict the value of ROC-optimized
cutoff values for the prediction of cardiotoxicity or sub-CTX.
A P<0.05 was considered statistically significant. All statistical
analyses were implemented using the MedCalc software version 18.11.6 (MedCalc, Ostend, Belgium, 2019).

RESULTS
Clinical and CMR Data
Out of 61 patients, 47 (77%) had breast cancer, 11 (18%)
had non-Hodgkin, and 3 (5%) had Hodgkin lymphomas.
Patients who developed cardiotoxicity were older (66±10,
P=0.02), had higher T1 values (1030±37 ms), and lower
percentage of normal myocardium (67%±8; Table 1).
Chemotherapy included anthracyclines, taxanes, monoclonal antibodies, and alkylating agents in 60 (98%), 47
(77%), 18 (30%), and 17 (28%) patients, respectively.
Fewer patients (8 %) received radiation therapy.

Longitudinal CMR and Pharmacological
Data
Nine (15%) patients went through phases of sub-CTX and
cardiotoxicity, 26 (43%) showed only sub-CTX, whereas
26 (43%) exhibited no cardiotoxicity. Of 35 patients with

cardiotoxicity or sub-CTX, 24 (69%) achieved REC in at
least one of the follow-up CMR scans.
At least 2 follow-up CMR scans, after 5±2 months
and 8±4 months, respectively, were available in all patients. Three, 4, and 5 follow-up CMR scans respectively were available in 58 (95%; 15±5 months), 48 (79%;
26±11 months), and 20 (33%) patients (29±7 months).
β-Blockers and ACE inhibitors or ARBs were administrated in 24 (39%) and 32 (52%) patients, respectively.
Twenty-one (34%) received combination therapy with
β-Blockers and ACE inhibitors or ARBs.

Time Response of CMR Variables in
Patients Without Cardiotoxicity and With
Cardiotoxicity Versus Without REC
Looking at the time response of CMR variables during
chemotherapy, normal myocardium (%) clearly differentiated between cardiotoxicity and non-cardiotoxicity
(with and without subsequent REC) during the early
stages after initiation of chemotherapy and simultaneously separated patients with cardiotoxicity and nonREC from those with REC during later stages. With LVEF,
differences between the 3 groups were significant only
during the first follow-up CMR scan and not throughout all other time points (Figure 1A and 1B).
The time response for cardiac biomarkers troponin I and BNP are provided in Figure I in the Data
Supplement.

Correlative Analysis and Detection of
Cardiotoxicity
Good correlations were shown between global CS,
GLS, and normal myocardium (%) Figure 2A and 2B. A
moderate correlation, however, was observed between
normal myocardium (%) and LVEF (Figure 2C). This was
attributed to the presence of diminished strain with
preserved LVEF≥53%, in patients with sub-CTX or CTX
(green points within the dashed box in Figure 2C).
In addition, normal myocardium (%) demonstrated
superior diagnostic value over T1, T2, BNP, and troponin
I (Figure II in the Data Supplement). Corresponding sensitivities and specificities for sub-CTX and cardiotoxicity
detection are shown in Table 2.

Cardiotoxicity Prediction and Prediction
of REC After Occurrence of Cardiotoxicity
Baseline normal myocardium (%) but not LVEF significantly differed between patients with subsequent subCTX and cardiotoxicity versus those without cardiotoxicity (Figure 3A and 3B).
Thus, baseline normal myocardium (%) but not LVEF%
enabled prediction of cardiotoxicity (Figure 3C), whereas
normal myocardium (%) after occurrence of cardiotoxicity and before initiation of cardioprotective therapy
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Table 1.

Clinical and Baseline CMR Data

Parameters

All patients (n=61)

No CTX (n=26)

Sub-CTX (n=26)

CTX (n=9)

P values

Clinical data
Age, y

54±15

51±13

53±16

66±10

0.015

Female sex

50 (82%)

23 (88%)

21 (81%)

6 (67%)

0.20

Breast cancer

47 (77%)

24 (92%)

19 (73%)

4 (44%)

0.009

Hodgkin lymphoma

3 (5%)

0 (0%)

1 (4%)

2 (22%)

0.027

Non-Hodgkin lymphoma

11 (18%)

2 (8%)

6 (23%)

3 (33%)

0.16

Arterial hypertension

22 (36%)

7 (27%)

10 (38%)

5 (55%)

0.30

Hyperlipidemia

9 (15%)

4 (15%)

5 (19%)

0 (0%)

0.38

Diabetes

4 (7%)

1 (4%)

2 (8%)

1 (11%)

0.72

Prior or current smoking

20 (33%)

7 (27%)

8 (31%)

5 (55%)

0.29

BMI, kg/m

25 (22–28)

25 (22–27)

25 (23–30)

25 (22–28)

0.45

2

Baseline CMR data
LVEF, %

61±5

61±5

62±4

57±5

0.07

LVEDV, mL

139±26

135±22

140±28

145±30

0.57

LVESV, mL

54±14

53±12

53±12

62±18

0.15

Septal wall thickness, mm

8.2±2.1

7.3±1.6

8.5±2.2

9.9±2.6

0.005

T1 values, ms

1055±36

1053±28

1066±39

1030±37

0.03

T2 values, ms

56±4

55±3

56±4

57±5

0.62

LV mass, g

96±14

92±16

98±11

102±15

0.08

LV mass index, g/m2

52±6

51±7

52±6

54±6

0.45
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GLS, %

−20±2

−21±2

−20±2

−19±2

0.06

GCS, %

−20±2

−21±1

−19±2

−18±1

<0.001

Normal myocardium, %

79±11%

84±8

76±10

67±8

<0.001

0.01 (0.01–0.01)

0.01 (0.01–0.01)

0.01 (0.01–0.01)

0.01 (0.01–0.01)

0.80

Laboratory data
Troponin I, ng/mL
BNP, pg/mL

26 (17–39)

26 (22–40)

20 (14–31)

38 (18–44)

0.57

Creatinine, mg/dL

0.77 (0.70–0.81)

0.76 (0.67–0.78)

0.73 (0.66–0.82)

0.78 (0.73–0.84)

0.70

Normal myocardium (%) denotes percent of normal segments with myocardial strain ≤−17%. BMI indicates body mass index; BNP, brain natriuretic peptide; CMR,
cardiovascular magnetic resonance; CTX, clinical cardiotoxicity; GCS, global circumferential strain; GLS, global longitudinal strain; LV, left ventricular; LVEDV, left
ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; LVESV, left ventricular end-systolic volume; and sub-CTX, subclinical cardiotoxicity.

accurately predicted REC (Figure 3D and Table 3). In addition, normal myocardium (%) was the only parameter
independently related to cardiotoxicity and to REC prediction in multiple regression analysis (Tables 4 and 5).

Kaplan-Meier Curves
Normal myocardium differentiated patients with from
those without subsequent cardiotoxicity (χ2=15.3,
P<0.001, hazard ratio, 4.2; Figures 4A and 4B) and simultaneously predicted REC after occurrence of cardiotoxicity during follow-up (χ2=4.6, P=0.03, hazard ratio,
6.6), which was not possible by any other CMR parameters or laboratory parameters (not shown).
Representative images: Cine, fast-SENC, and T1
mapping images in the same patient at baseline (Figure IIIA through IIIE), after occurrence of cardiotoxicity (Figure IIIF through IIIJ), and during REC (Figure IIIK
through IIIO) can be appreciated in Figure III in the Data
Supplement.

DISCUSSION
The following main findings were established in our
study:
1. A short duration noncontrast CMR scan, lasting 10
to 12 minutes (Figure IIIP in the Data Supplement)
can be serially performed in patients undergoing
chemotherapy for cancer, contributing to early
detection and prediction of cardiotoxicity and with
zero radiation or contrast agent exposure.
2. Normal myocardium (%) promptly identifies
changes during chemotherapy, allowing for the
accurate detection of sub-CTX and cardiotoxicity
and for strain normalization during cardioprotective medication. Corresponding changes in terms
of LVEF, troponins, and BNP appear delayed compared with normal myocardium (%).
3. Normal myocardium (%) can predict cardiotoxicity in contrast to all other imaging data, clinical
data, or laboratory markers.
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Figure 1. Evolution of the studied parameters over time in patients without clinical cardiotoxicity (no CTX), those with CTX without recovery from
cardiotoxicity (CTX wo REC) and those who achieved REC.
(A) Normal myocardium (%), (B) left ventricular ejection fraction. wo indicates without.

Downloaded from http://ahajournals.org by on September 15, 2022
Figure 2. Correlation between strain, left ventricular ejection fraction (EF), and normal myocardium (%).
(A) Correlation between circumferential strain and normal myocardium (%). (B) Correlation between longitudinal strain and normal myocardium (%). (C) Correlation between left ventricular EF and normal myocardium. CTX indicates clinical cardiotoxicity; and sub-CTX, subclinical cardiotoxicity.
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Table 2.

Sensitivities, Specificities, and AUC for the Sub-CTX and CTX Detection
Cutoff values

Sensitivity (%)

Specificity (%)

AUC

P values

Normal myocardium, %

70%

95%

80%

0.96

<0.001

LVEF, %

53%

54%

85%

0.76

<0.001

Detection of either sub-CTX or CTX

Troponin I, ng/mL

0.01

58%

94%

0.77

<0.001

BNP, pg/mL

44

55%

78%

0.63

0.019

70%

93%

80%

0.94

<0.001

Detection of sub-CTX
Normal myocardium, %
LVEF, %

58%

63%

68%

0.70

<0.001

Troponin I, ng/mL

0.01

55%

94%

0.75

<0.001

BNP, pg/mL

44

40%

78%

0.56

0.41

51%

85%

100%

0.99

<0.001

Detection of CTX
Normal myocardium, %
LVEF, %

55%

90%

85%

0.94

<0.001

Troponin I, ng/mL

0.025

65%

100%

0.81

<0.001

BNP, pg/mL

44

80%

78%

0.76

<0.001

Normal myocardium (%) denotes percent of normal segments with myocardial strain ≤−17%. AUC indicates areas under the curve;
BNP, brain natriuretic peptide; CTX, clinical cardiotoxicity; LVEF, left ventricular ejection fraction; and sub-CTX, subclinical cardiotoxicity.

4. Normal myocardium (%) also predicts responsiveness to cardioprotective treatment after
occurrence of cardiotoxicity and initiation of cardioprotective therapy, thus identifying patients
with higher chances for REC.
Downloaded from http://ahajournals.org by on September 15, 2022

Identifying Cardiotoxicity
Recognizing the adverse effects of various chemotherapeutic agents on myocardial function led to the development of a multidisciplinary integrative approach,
cardio-oncology, to assist with management of patients
with cancer.3,17 Thus, as an increasing number of patients survive their cancers, their long-term prognosis
will be adversely impacted by the risk of developing cardiovascular complications.12
A major concern for cardio-oncologists is the timely
recognition of myocardial dysfunction in the context
of administration of cardiotoxic agents. A significant
proportion of patients, reaching up to 30%, have been
shown to have reductions in LVEF without symptoms.18,19
Moreover, many patients who develop a reduced LVEF
do not show significant improvements, even when the
cardiotoxic therapy is stopped, and proper heart failure
management is initiated.20 Thus, using LVEF as a marker
for cardiotoxicity might prove insufficient for these patients. Our data displayed a similar pattern, where reductions in LVEF exhibited lower accuracy than normal
myocardium (%) for the detection of cardiotoxicity.
CMR represents an excellent tool for monitoring the
cardiovascular health of patients with cancer. Its lack
of ionizing radiation and excellent reproducibility in assessing myocardial volumes and mass make this method suitable for the longitudinal evaluation of patients

undergoing chemotherapy. CMR-derived myocardial
strain using fast-SENC exhibits excellent inter and intraobserver variabilities.21,22 In addition, fast-SENC exhibits lower variability for the assessment of segmental
strain compared with other CMR-based methods, such
as feature tracking, thus increasing the consistency of
the measurements in longitudinal studies.23 Recently,
we demonstrated the ability of fast-SENC for the diagnostic classification and risk stratification of patients
with heart failure in a large patient cohort of 1169
consecutive patients.11 Here, normal myocardium (%)
precisely predicted the occurrence of heart failure in asymptomatic individuals and readily detected subclinical
LV dysfunction even in patients at risk for heart failure
without structural or functional heart disease, a subgroup which closely resembles to date healthy patients
who are exposed to cardiotoxic agents.24
In previous studies using CMR, a decrease in LVEF and
circumferential strain was noted in patients with breast
cancer undergoing anthracycline therapy.25 Similarly, we
found fast-SENC derived myocardial strain, and especially normal myocardium (%), to be an excellent parameter
for identifying cardiotoxicity. CMR can also provide information related to the presence of inflammation and
fibrotic tissue in the myocardium with the help of T1 and
T2 mapping.26 This would be especially helpful in patients
who receive anthracyclines because these compounds
may produce edema and fibrosis.27 However, we failed
to identify a significant role of T1 and T2 values in the
diagnosis of sub-CTX and cardiotoxicity in our study. This
is in concordance with a recent study by Altaha et al,28
who noted significant overlap, between patients with
cardiotoxicity and healthy control in the measurement of
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Figure 3. Evaluation of the baseline values of normal myocardium (%) and left ventricular ejection fraction and prediction of cardiotoxicity (CTX)
and recovery (REC).
A, Differences between baseline values of (A) normal myocardium (%) and (B) left ventricular ejection fraction (LVEF) in patients with versus without CTX.
C, Receiver operating characteristic (ROC) analysis for CTX prediction based on baseline cardiovascular magnetic resonance (CMR) values. D, ROC analysis for the
prediction of REC in patients who had CTX and received cardioprotective treatment with β-blockers, ACE (angiotensin-converting enzyme)/angiotensin II receptor
blockers or combination of both (Note that pooled data were used for this analysis, derived from CMR examinations just before the initiation of the cardioprotective therapies). AUC indicates areas under the curve.

T1 and T2 values, making it exceedingly difficult to derive
cutoff values for the individual detection of sub-CTX.
Myocardial strain measured with echocardiography
was also proven to be a valuable tool for the workup
of patients with cancer.29,30 Despite its wide availability,
good practicability, and cost-efficiency, however, echocardiography may be limited due to its dependency on
the acoustic window of the patients and the skills of the
operator. In addition, high intervendor, interobserver, and
intraobserver variabilities have been mentioned previously with echocardiography.31,32 Moreover, the feasibility
of 3-dimensional echocardiography derived myocardial
strain in selected population can be as low as 85%.33
Cardiac biomarkers are also seen as possible good
indicators of subclinical dysfunction. Indeed, the serial
evaluation of cardiac troponin demonstrated promising
results in patients undergoing anthracycline therapy.34
Moreover, increased levels of cardiac troponins appear to
identify patients who would not recover LVEF after chemotherapy.35 Similarly, BNP and NT-proBNP (N-terminal

pro-B-type natriuretic peptide) can help in the early recognition of cardiotoxicity.36 However, the optimal time
point for such measurements is still unclear. Furthermore,
it is unclear if cardiac biomarkers can promptly detect
subtle myocardial damage, as experienced in sub-CTX.
Indeed, in our cohort, increases in cardiac troponin and
NT-pro BNP were seen firstly at the second visit, like the
changes seen with LVEF, that is, at a time point where
myocardial damage already may be irreversible.

Predicting Cardiotoxicity
Although identifying cardiotoxicity is an especially important end point in the workup of patients with cancer
receiving cardiotoxic chemotherapy, predicting which
patients would be at risk of developing cardiac dysfunction before starting the chemotherapeutic agent would
significantly increase the likelihood of early cardiotoxicity recognition and aid in proper clinical management. To
date, very few prediction models address the question
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Table 3.

Sensitivities, Specificities, and AUC for Sub-CTX and CTX Prediction
Cutoff values

Sensitivity, %

Specificity, %

AUC

P values

Prediction of CTX
Normal myocardium, %

80%

71%

74%

0.76

<0.001

LVEF, %

65%

85%

22%

0.52

0.80

Troponin I, ng/mL

0.01

4%

100%

0.52

0.32

BNP, pg/mL

20

46%

79%

0.55

0.65

55%

63%

100%

0.84

<0.001

Prediction of REC
Normal myocardium, %
LVEF, %

50%

13%

83%

0.55

0.79

Troponin I, ng/mL

0.02

89%

33%

0.58

0.86

BNP, pg/mL

50

50%

100%

0.67

0.28

Normal myocardium (%) denotes percent of normal segments with myocardial strain ≤−17%. AUC indicates areas under
the curve; BNP, brain natriuretic peptide; CTX, clinical cardiotoxicity; LVEF, left ventricular ejection fraction; REC, recovery; and
sub-CTX, subclinical cardiotoxicity.
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of cardiotoxicity prediction in such patients.4 They are
mostly based on clinical and demographic data and
have a low sensitivity so that many patients who would
not meet the criteria of high-risk patients may still develop cardiotoxicity.17 We were able to demonstrate a
role of normal myocardium (%) for the identification of
patients who subsequently develop cardiotoxicity. This is
again in agreement with our recent findings, where asymptomatic patients at risk for heart failure and without
structural or functional heart disorders exhibit reduced
normal myocardium (%) by strain11 and may, therefore,
potentially be at risk for developing overt heart failure in
the long- or short term, respectively, if continuously exposed to risk factors such as diabetes or hypertension or
to cardiotoxic agents. Interestingly, the ROC-optimized
cutoff value of normal myocardium<80%, for the detection and for the prediction of subsequent cardiotoxicity in our present cohort, was identical to the one differentiating healthy subjects from those with subclinical
LV dysfunction and thus at risk for future heart failure
in recent studies.11 The predictive value of normal myocardium was independent of age, clinical heart failure
symptoms, and cardiac biomarkers and is to our knowledge the first time, that an imaging marker achieves
prediction of cardiotoxicity based on baseline scans.
In addition, our study is the first to incorporate cine,
strain, and T1 and T2 parameters, as well as biomarkers

obtained before the initiation of therapy, to identify
which tools and parameters are best suited for the clinician for the prediction and detection of cardiotoxicity.
Previous CMR studies rather focused on conventional
parameters, such as LV mass and LVEF.10

Table 4. Multiple Regression Analysis for Predicting CTX Using Baseline Parameters

Table 5. Multiple Regression Analysis for Predicting REC Using Parameters Before the Initiation of Cardioprotective Therapy

Coefficients

P values

Normal myocardium, %)

−2.2

0.0001

LVEF, %

−0.13

0.52

NYHA class

0.007

T1, ms

0.0001

Role of Cardioprotection
All efforts invested in the prediction of cardiotoxicity
and the early detection of sub-CTX aim at establishing
an optimal time point of treatment with cardioprotective therapies. To date, few studies have evaluated the
role of ACE inhibitors or ARBs and β-blockers in these
patients. A study by Cardinale et al7 investigated the
effect of enalapril and whenever possible carvedilol
in 201 patients who developed overt LV dysfunction
(LVEF<45%) during anthracycline therapy. They found
an improvement in LVEF in 55% of patients over a period of 36 months. However, when the same group analyzed over 2000 patients with anthracycline-induced LV
dysfunction over a period of over 5 years, they found
that only 11% of patients achieved complete recovery.20 In both studies, the trigger for initiating cardioprotective medication was a clear reduction in LVEF,
that is, a time point where a significant proportion of
cardiomyocytes is already irreversibly affected. A more
recent randomized study by Gulati et al37 showed the

Coefficient

P values

Normal myocardium, %

2.54

0.004

LVEF, %

−0.013

0.25

0.38

NYHA class

0.07

0.53

0.95

T1, ms

0.002

0.24

Normal myocardium (%) denotes percent of normal segments with myocardial strain ≤−17%. CTX indicates clinical cardiotoxicity; LVEF, left ventricular
ejection fraction; and NYHA, New York Heart Association.

Normal myocardium (%) denotes percent of normal segments with myocardial strain ≤−17%. LVEF indicates left ventricular ejection fraction; NYHA, New
York Heart Association; and REC, recovery from cardiotoxicity.
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Figure 4. Normal myocardium (%) as predictor of cardiotoxicity.
Normal myocardium<80% (A) at baseline and <55% (B) during follow-up cardiovascular magnetic resonance scans both accurately differentiated
patients with from those without subsequent clinical cardiotoxicity (CTX) and patients with recovery from cardiotoxicity (REC) versus non-REC after CTX occurrence
and initiation of cardioprotective treatment, respectively. Normal myo. (%) indicates normal myocardium (%); and ROC, receiver operating characteristic.
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cardioprotective effect of candesartan when administrated in patients with breast cancer who received
anthracycline-based regimes with or without adjuvant
trastuzumab. In our study, and in concordance with the
current recommendations, cardioprotective therapy
was initiated early based on data provided from imaging studies, including strain.15,38 This resulted in a consecutive improvement of CMR parameters of LV-function and strain in over 2 out of 3 (69%) of our patients
with sub-CTX and cardiotoxicity during follow-up. As
the percentage of patients achieving REC is markedly
higher, than that reported in the current literature,
this implies that closer follow-up of such patients is
clinically useful.17 In addition, normal myocardium (%)
predicted REC after occurrence of cardiotoxicity in this
context, which reaffirms the role of myocardial strain
for the longitudinal workup of such patients. Interestingly, the ROC-optimized cutoff value of normal myocardium<55%, predicting lower chances for REC, was
close to the one (<60%) predicting clinical heart failure
end points in patients with subclinical LV dysfunction,
as recently reported.11 Thus, normal myocardium (%)
provides an additional diagnostic window to subtle
changes in cardiac function, which can be used for
monitoring cardiac safety during chemotherapy (Figure 5A). Based on these findings, we propose a potential algorithm for the management of patients with
cancer undergoing chemotherapy (Figure 5B). This algorithm may help avoiding irreversible damage of the
myocardium by the early initiation of cardioprotection
and the potential adjustment of chemotherapy regimens after consultation of the cardio-oncology team.

Limitations
Several limitations of our study need to be addressed.
First, this is a single-center study with a relatively low
number of patients. Moreover, the decision to begin
cardioprotective treatments was left at the discretion of
the attending cardiologist. Furthermore, the study was
nonrandomized, and no control group was present,
whereas some freedom of timing needs to be acknowledged regarding the follow-up CMR visits. In addition,
no standardized protocol was used for the administration of ACE inhibitors, ARBs, and β- blockers. However,
all the cardioprotective drugs used are recognized in the
heart failure guidelines for their beneficial effect in patients with reduced LVEF. Lastly, some patients received
concomitantly radiotherapy, which can also be responsible for reduced regional myocardial performance, which
is especially important in patients with breast cancer.30
However, the percentage of patients with concomitant
radiotherapy was relatively low. Lastly, third-generation
troponin I was used as marker of myocardial damage. It
is conceivable that the use of high-sensitive troponin assays would have provided more consistent results.

Conclusions
Normal myocardium (%) derived by serial fast-SENC
CMR acquisitions is an ideal tool for the longitudinal
study of patients undergoing chemotherapy due to
breast cancer or lymphoma. This parameter can both
predict the incidence of cardiotoxicity and detect subCTX earlier and with higher accuracy than conventional
CMR parameters and biochemical markers. The ability
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Figure 5. The role of normal myocardium (%) in the diagnostic evaluation of cancer patients.
A, Additional diagnostic window provided by normal myocardium (%) versus left ventricular (LV) ejection fraction for the prediction of clinical
cardiotoxicity (CTX) and for its early identification, allowing monitoring of cardiac safety during chemotherapy. B, Proposed clinical algorithm incorporating clinical
and cardiovascular magnetic resonance (CMR) data for the management of patients who undergo chemotherapy. CAD indicates coronary artery disease; REC,
recovery from cardiotoxicity; and ROC, recovery from cardiotoxicity.

of this imaging marker to reduce the occurrence of
cardiotoxicity merits further investigation in future randomized studies.
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